



15 July

**Success story of a relapsing alveolar rhabdomyosarcoma:
importance of complete local treatment!**

Morgane Cleirec



I am a pediatric oncologist, working at the university hospital in Nantes, France. I also spent a year in the Reunion Island. I currently work in a unit treating children with solid and hematologic malignancies. I have a special interest for sarcomas, and take part to some expert groups of the French Society of Oncology and Hematology. I am involved in the Young SIOPE and participate to the Essential Medicines Group.

Hans Merks



Hans Merks has focused his clinical and research activities on pediatric soft tissue and bone sarcoma, and cancer predisposition syndromes. He is Chair of the European pediatric Soft tissue sarcoma Study Group (EpSSG), and Deputy Chair of the Euro Ewing Consortium Executive Committee. He is co-investigator of the European Frontline and Relapsed-Rhabdomyosarcoma Study (FaR-RMS Study) that will enroll patients from 2020-2027.

Hans Merks is Principal Investigator at the Princess Maxima Center for Pediatric Oncology in Utrecht and leads a Pediatric Sarcoma Imaging Group that aims to design and implement innovative imaging studies to identify early prognostic and predictive biomarkers in clinical trials and individual patient care, and optimize staging. Furthermore, his group focusses on functional outcome and quality of life after local therapy for soft tissue and bone sarcoma in children, with the goal to optimize care and generate prediction models for local therapy related adverse effects and functional outcome, which will optimize shared decision making.